LinkedIn IconTwitter Icon
14-16 November 2017
The Westin Grand Munich, Germany

2016 Speakers

Expand/Collapse

Udo Gaipl
Head of Radiation Immunobiology
University Hospital Erlangen

Since 2007 Dr. Gaipl heads the Radiation Immunobiology and is coordinator of the network Immunobiology of the German Society for Radiation Oncology. He obtained his Dr. rer. nat. in 2003 for studies on the role of complement and DNase I in the opsonisation and clearance of dying cells. Following the PostDoc research in the EU-project APOCLEAR in close co-operation with the Clinical Immunology Unit at the Hospitale San Raffaele in Milano, he continued his work in Erlangen on dying and dead cells as inducer of chronic autoimmunity and as tool for immune intervention. He obtained the venia legendi for Experimental Medicine in 2009 and since 2015 he is Professor for Experimental Medicine with specialization on translational radiation oncology. We examine “targeted” (DNA-damage and DNA-repair) and „non-targeted“ (abscopal immune-mediated) effects of radiation and perform detailed immunomonitoring of patients during radiochemotherapy and patients exposed to low doses of radiation. Focus is set in pre-clinical tumor and inflammation models and in immunophenotyping of patients on immune modulations by combination of radiation with immunotherapy (autologous whole tumor cell vaccines generated with high-hydrostatic pressure technology, hyperthermia and immune checkpoint blockade) as well as on anti-inflammatory modes of action of low doses of radiation, including radiation protection issues.

Day Two

Thursday 16th November, 2017

14.45 | Combining Radiotherapy & Immune Modulators

Neil Williams
CSO & Founder
KWS Biotest

Professor Neil Williams is Founder and Chief Scientific Officer of KWS BioTest Ltd.  He was also Founder of Trident Pharmaceuticals Inc, and inventor of their novel T regulatory cell modulating therapy. His positions have included Professor of Immunology and Research Director at the University of Bristol, Chairman of the British Society for Immunology and he has acted as a member of the Discovery Panel at Cancer Research Technology. He brings a huge depth of expertise in immunology and inflammation, and has led a range of programs aimed at the development of novel cancer vaccines and immune modulating therapies. Professor Williams' expertise in drug discovery enables KWS BioTest to act as true partners for their many clients across Europe and the rest of the world. KWS employs a range of cell biology, analytical and pharmacology models to determine mechanism of action, screen novel compounds and develop novel PD biomarkers in order to predict efficacy in pre-clinical and clinical settings

Day One

Wednesday 15th November, 2017

13.45 | Modelling Aspects of the TME in Order to Guide Development of Novel Immune Modulating Cancer Therapies

Frederic Triebel
CSO & CMO
Prima Biomed Ltd

Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001). Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while being also involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical haematologist, Dr. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics, leading to 145 publications and 18 patents. Immutep is now part of Prima Biomed Ltd and Dr. Triebel serves as the CSO/CMO of the company.

Day Two

Thursday 16th November, 2017

13.15 | Combination Strategies for LAG-3Ig (IMP321) With Either Chemotherapy or Anti-PD-1 Therapy

Jon M. Wigginton
Chief Medical Officer and Senior Vice President of Clinical Development
MacroGenics, Inc

Jon Wigginton, MD currently serves as Chief Medical Officer and Senior Vice President of Clinical Development at MacroGenics, Inc., a Maryland  biotechnology company focused on immunotherapeutic approaches for cancer and autoimmune disease.  Dr. Wigginton previously served as Therapeutic Area Head of Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno-Oncology portfolio including anti-PD-1, anti-PD-L1 and various immunotherapy combinations including anti-CTLA-4/anti-PD-1 among others. He also served in a governance leadership role for discovery efforts in immuno-oncology at BMS.  Prior to joining BMS, Dr. Wigginton served as Director of Clinical Oncology at Merck Research Laboratories, where he led early- and late-stage clinical development teams for small molecules and biologics. During his academic career, Dr. Wigginton held several positions at the National Cancer Institute, Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch, where he led an integrated basic science and early clinical research effort focused on combination immunotherapy. Dr. Wigginton also served previously as President of the International Society for the Biological Therapy of Cancer (now the Society for Immunotherapy of Cancer).  He received his B.S. in Biology and his M.D. from the University of Michigan.

Day Two

Thursday 16th November, 2017

11.15 | Combination Immunotherapy Using Coordinate Checkpoint Blockade with Bispecific Molecules

Mark Paris
Associate Director, Translational Applications
Mitra Biotech

     

Day One

Wednesday 15th November, 2017

14.45 | CANscript: A Clinically Validated, Ex Vivo Tumor Culture Platform for Interrogating Response to Drug Treatment

Philipp Müller
Principal Scientist, Research & Development
Boehringer Ingelheim Pharma GmbH & Co. KG

Dr. Philipp Müller received his PhD in Biochemistry from the University of Basel in 2009 (Biozentrum, Prof. Jean Pieters), with a major focus on the immunology of infectious diseases, immune cell signaling and in vivo models of immune cell function as well as development. During the last 8 years his research has been dedicated to cancer immunology and immunotherapy. He has worked on and published in high ranking journals on the immune-promoting properties of Antibody-Drug-Conjugates, bispecific antibody formats as well as agonistic antibodies, such as anti-CD40, and their therapeutic combination with immune-checkpoint blockade. Dr. Philipp Müller is currently working as Principal Scientist within the Cancer Immunology & Immune Modulation Department of Boehringer Ingelheim (Biberach an der Riß, Germany) with a major focus on cancer vaccines and oncolytic viruses.

Day Two

Thursday 16th November, 2017

09.45 | VSV-GP: A Game Changer for Immuno-Oncology

Shane Olwill
Vice President, Development and Head, Immuno-Oncology
Pieris Pharmaceuticals, Inc

Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Shane was Director of Research at Fusion Antibodies Ltd where he was responsible for the discovery and development of multiple drug candidates. He is a named inventor on 16 patents and has published his research in many international peer review journals. Shane received his PhD in Molecular Hematology / Oncology from University of Ulster, following which he worked as an industrial postdoc in conjunction with University College Cork. Shane has a PgDip in Management Practice from DIT Business School and is a state qualified Medical Scientist.

Day Two

Thursday 16th November, 2017

11.45 | Bispecific TNFR-Superfamily Agonists for Tumour Localised Immune Modulation

Carine Paturel
Director, Research and Drug Development
Innate Pharma

Day One

Wednesday 15th November, 2017

16.45 | Panel Discussion: Determinants Of Sensitivity & Resistance To Immune Checkpoint Blockers In Solid Tumours

16.15 | Targeting CD39 and CD73 to Improve Anti-Tumour Immune Responses

Peter Steinberger
Associate Professor
Medical University of Vienna

Peter Steinberger has studied Biology in Graz and Vienna and did his Ph.D. under the supervision of Rudolf Valenta at the University of Vienna (1992-1996). Following postdoctoral studies with Carlos Barbas 3rd at The Scripps Research Institute in San Diego, California (1996-1999), he joined the group of Walter Knapp at the Institute of Immunology. Since 2007 he heads the research group “Immune Receptors and T cell activation” at this institution. His research focuses on receptor-ligand interaction and the regulation of T cell responses. A major part of his work deals with costimulatory and coinhibitory pathways that promote or inhibit human T cell responses, respectively. His group engineers molecular and cellular tools to dissect the role of individual receptors to T cell activation processes.

Day One

Wednesday 15th November, 2017

14.15 | A Cellular Platform for the Evaluation of Immune Checkpoints

Anne Månsson Kvarnhammar
Senior Scientist, Research & Development
Alligator Bioscience

Dr. Anne Månsson Kvarnhammar earned her Ph.D 2009 at Lund University, Sweden, working on the immune response in allergic rhinitis. This area was further pursued during a postdoc position at Karolinska institutet. In 2012, Dr. Kvarnhammar joined Novo Nordisk, Denmark, working with developing in silico and in vitro models to predict and reduce the clinical immunogenicity to biologics as well as novel tolerance concept. In February 2017, Dr. Kvarnhammar joined Alligator Bioscience, and as Senior Scientist she is In vitro and Scientific Lead for several projects, including ATOR-1015.

Day One

Wednesday 15th November, 2017

15.45 | Generation of a Bispecific Immunomodulatory Antibody ATOR-1015 Targeting OX40 and CTLA-4

Tom Lillie
VP, Head of European Clinical Development
Merck Sharp & Dohme

Tom completed his undergraduate training at Brasenose College, University of Oxford, where he was awarded a first class degree in pharmacology, cell biology and immunology, before earning his doctorate from the Department of Physiology at the University College of London.  He then completed his medical education at the University College London Medical School, receiving honors distinction in clinical pharmacology and surgery. He is a member of the Royal College of Surgeons of England and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. Tom has led global, regional and affiliate medical teams, encompassing both clinical development and medical affairs functions. He has extensive experience in clinical research in phase 2 – phase 4, and in supporting regulatory, safety and reimbursement interactions. During his clinical and industry career he has specialised in oncology & haematology, but has also worked in cardiovascular and neurologic disease areas.

Day One

Wednesday 15th November, 2017

11.30 | Panel Discussion: Challenges & Perspectives of Immunotherapy Biomarkers

08.30 | Exploring Immuno-Oncology Combinations – Biology, Big Data & Biomarkers

08.20 | Chairs Opening Remarks

Krzysztof Masternak
Head of Biology
Novimmune SA

Krzysztof Masternak is Head of Biology at Novimmune (Geneva, Switzerland). Currently leads immuno-oncology bispecific antibody projects, from discovery (candidate selection, characterization, and validation) to mechanism of action and in vivo translational studies. He was previously involved in discovery and development of monoclonal antibodies for inflammation/autoimmunity. Krzysztof holds a Ph.D. from the University of Lausanne.

Day One

Wednesday 15th November, 2017

16.45 | Panel Discussion: Determinants Of Sensitivity & Resistance To Immune Checkpoint Blockers In Solid Tumours

Day Two

Thursday 16th November, 2017

13.45 | CD47 Neutralising Bispecific Antibodies Promote Adaptive Anti Tumour Immunity

Lucie Heinzerling
Head of Dermatooncology and Head of Biomarker Research Group
University Hospital Erlangen

Lucie Heinzerling is Professor of Dermatology and Head of the Biomarker Research Group at the University Hospital Erlangen. After her PhD in Immunology at the Charité she worked at the University Zurich (Medical Virology) and at the University hospital Zurich (Dermatology) and could thus conduct several translational phase 1 Investigator-initiated trials (IITs) for melanoma and lymphoma using gene therapy and oncolytic viruses. At the Ludwig Institute for Cancer Research, Melbourne, she conducted a project on lymphangiogenesis. After a position as business consultant at McKinsey & Company she returned to academia at the Charité Berlin as quality manager within an EU-health network leading a network of 25 centers in 19 countries. She obtained her Master of Public Health at Harvard University and is board certified for medical tumor therapy, allergies, and quality management. She has also consulted for the World bank, for several biotech companies and for the MIT-associated Poverty Action Lab. Currently, she is head of Dermatoonkology at the University hospital Erlangen and conducts translational research in biomarkers and melanoma therapy.

Day Two

Thursday 16th November, 2017

15.45 | Rationale From Biological & Clinical Data: Strategies for Combining & Sequencing Checkpoint Inhibitors With Other Agents

R.P. (Kris) Iyer, Ph.D.
Co-Founder & Chief Scientific Officer
Spring Bank Pharmaceuticals Inc.

R. P. Iyer, (Kris) is the co-founder and Chief Scientific Officer of Spring Bank Pharmaceuticals. He has more than 25 years’ experience in drug discovery and development in diverse fields including antivirals, inflammation, and immune-oncology.   Kris is internationally recognized as an innovator in the fields of nucleic acid chemistry, bioorganic chemistry, and pharmaceutical sciences with over 100 publications and 200 issued and filed US and international patents. Prior to Spring Bank, Kris was the co-founder and VP of Discovery at Origenix Technologies.

Alan Cuthbertson
Head of Thorium Research
Bayer

Alan Cuthbertson is Head of Thorium Research at Bayer AS with responsibility for the development of a new class of alpha-particle emitting targeted antibody conjugate for the treatment of cancer. He joined Bayer through the acquisition and integration of Algeta ASA where he served as SVP R&D with the goal translating the targeted thorium-227 conjugate (TTC) platform from research to clinical phase, a role he continues with today. Alan was previously Head of Global Chemistry R&D at GE Healthcare working with the development of novel radiopharmaceuticals for a variety of medical diagnostic applications. He has a PhD in Chemistry from The University of Edinburgh.

Day Two

Thursday 16th November, 2017

15.15 | Targeted Thorium Conjugates & the Potential of Combination Strategies with ICI

Arnold B Gelb
Clinical Advisor
EMD Serono

Arnold B Gelb, MD, MS, DABP, FASCP, FCAP is presently a Clinical Advisor at EMD Serono Research and Development Institute, Inc., a business of Merck, KGaA, Darmstadt, Germany.  He helps drive strategy and implementation of tissue-based exploratory biomarkers and companion diagnostics for clinical development programs, with a focus in immuno-oncology. He previously held progressive positions through Senior Medical Director in biomarkers, companion diagnostics and/or pathology, including at Halozyme Therapeutics, Quest Diagnostics Clinical Trials, Novartis, and the faculty of the University of California, San Francisco.  He is board certified pathologist with immuno-pathology and molecular pathology experience, who trained at the University of California, San Francisco, Stanford University, and the University of Chicago. He earned his medical degree from Stanford University where he was a Stanford Medical Scholar, following graduate studies in the Harvard-MIT Division of Health Sciences.

Day One

Wednesday 15th November, 2017

11.30 | Panel Discussion: Challenges & Perspectives of Immunotherapy Biomarkers

11.00 | The Interrelationships Between Mutational Load, Mismatch Repair, & Immune Checkpoint Expression

Markus Hecht
Medical Doctor, Radiology
University Hospital Erlangen

Markus Hecht is radiation oncologist at the Universitätsklinikum of the Friedrich-Alexander-Universität Erlangen-Nürnberg. In his medical dissertation he focused on radiosensitizing effects of antiretroviral drugs. In 2011 he started his clinical training in radiation oncology. As the first patients with a clinically relevant increased radiosensitivity due to BRAF inhibitor treatment appeared he focused on this interaction during his PostDoc rotation to the Interdisciplinary Center for Clinical Research (IZKF) Erlangen. His results are the current reference work that is the basis for clinical decisions and the recently published Eastern Cooperative Oncology Group (ECOG) guideline. Since 2014 he continues his clinical specialization in radiation oncology. He is member of the Advisory Committee on Radiation Oncology Practice (ACROP) for the combination of radiotherapy and targeted therapy of the European Society of Radiation Oncology (ESTRO). In his current translational research he focuses on effects of radiochemotherapy and radioimmunotherapy on the tumor microenvironment in patient tissue and blood samples.  The effects on tumor infiltrating lymphocytes and immunological biomarkers are of particular interest. These analyses may help to identify possibilities to combine immune modulating agents to current treatment schemes in radiation oncology. He is sub-principal investigator in different clinical trials combining radiotherapy with immune checkpoint inhibitors.

Day Two

Thursday 16th November, 2017

14.45 | Combining Radiotherapy & Immune Modulators

Hubertus Hochrein
Head of Research
Bavarian Nordic

Over 20 years of experience in immunological research both in academia and in industry, including work with various pattern recognition receptors, dendritic cells, T-cell subsets, various pathogens and tumor immunotherapies. A strong background in innate and adaptive immunology on pathogen-host interaction, infection immunology and tumor immunology. Successfully participated in the development of vaccines for tumor therapy and to various pathogens and the transition from pre-clinical to clinical application. Heading the research line of Bavarian Nordic responsible for employees from various departments.

Day One

Wednesday 15th November, 2017

16.45 | Panel Discussion: Determinants Of Sensitivity & Resistance To Immune Checkpoint Blockers In Solid Tumours

13.15 | Requirements for Improved Preclinical Models for More Rapid Clinical Development in Immuno-Oncology

Roy Baynes
Senior Vice President and Head, Global Clinical Development
Merck Sharp & Dohme

Roy Baynes is Senior Vice President Global Clinical Development and Chief Medical Officer at Merck Research Laboratories in Rahway, New Jersey. He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.

Day Two

Thursday 16th November, 2017

09.00 | Keynote - Shifting Paradigms in the Combination Setting

Jannie Borst
Head of Division, Immunology
Netherlands Cancer Institute

Jannie Borst obtained an MSc degree in biology with chemistry and a PhD degree in molecular immunology from Leiden University. She did her PhD work at Harvard Medical School in Boston with biochemist dr Cox Terhorst and trained in immunology with drs Jan de Vries and Hergen Spits from 1980 to 1985. She started her independent career as Principal Investigator (PI) at The Netherlands Cancer Institute (www.nki.nl) in 1987, obtained tenure in 1992 and became head of the Division of Immunology in 2002. From 1999 onwards, she is in addition professor in Experimental Oncology at the University of Amsterdam. Jannie Borst has received the Van Loghem career award of the Dutch Society for Immunology in 2009 and was elected EMBO member in 2012. As a PI, she maintains a research group of 10-12 people by means of competitive grants and has trained 17 PhD students. She has authored 165 peer-reviewed papers (H-index 67, >13.000 citations). Major contributions have been to the understanding of antigen recognition-, costimulatory receptor- and death receptor functions on lymphocytes. She currently studies the molecular basis of T-cell and dendritic cell function, a.o. by transcriptomics and proteomics. This work aims to improve cancer immunotherapy. To this end, collaborations with biotech, pharma and clinicians are in place.

Day Two

Thursday 16th November, 2017

10.15 | Functional Programs & Molecular Mechanisms that Optimise Cytotoxic T Cells (CTLs) for Their Anti-Tumour Efficacy

08.50 | Chairs Opening Remarks

Catherine Alix-Panabieres
Associate Professor & Director of the LCCRH
University Medical Centre of Montpellier

Dr Catherine Alix-Panabières received her PhD degree in 1998 at the Virology Institute, University-Louis-Pasteur, in Strasbourg. In 1999, she moved to Montpellier where she did a postdoctoral research and, in 2010, she achieved getting a permanent position at the Hospital and at the Faculty of Medicine of Montpellier (MCU-PH). As an associate professor, she is the new director of the Laboratory of Rare Human Circulating Cells (LCCRH) in the Department of Cell & Tissue Biopathology of tumors. In this unique LCCRH, they isolate, detect and characterize circulating tumor cells using combinations of EPISPOT, CellSearch®, the CellCollector, molecular biology, Parsortix and DEPArray for single cell sorting. She has authored >50 scientific publications in this field of Liquid Biopsy during the last years including 10 book chapters and she is part of two big European projects: CTC-SCAN (Transcan-project) and CANCER-ID (IMI-project). After she got the Scientific Prize given by the Region Languedoc-Roussillon in 2008, it was a great honor for her to receive the Gallet-et-Breton Cancer Prize, the highest honor conferred by the French Academy of Medicine in November 2012. Very recently, she got the AACR 2017 Award in Washington for the most cited scientific article in 2015 (Cayrefourcq et al. Cancer Res).

Day One

Wednesday 15th November, 2017

11.30 | Panel Discussion: Challenges & Perspectives of Immunotherapy Biomarkers

09.00 | Harnessing Liquid Biopsies for Disease Monitoring: The Evolving Role of Circulating Tumour Cells as Informative Biomarkers